Her background is IP law, with a degree in this too. She will be looking after alliance management, which for those not aware, relates to managing key deal terms & strategic partnerships etc. Joining the Therapeutics team at this stage is another big tick for preCISION & the Group.
I personally believe it to be the truth. Especially when you add it into the mix of other communications from the company over the last 6 months.
It clearly meant a lot to this person reading this other tweet:
"Hi Mick, there is nothing extra to share really. I asked the direct question and AS answered it. I was a little embarrassed that it was such a simple question but it was very important to me. He got that."
I was surprised this didn't have much of a reaction yesterday/today too. It's hugely significant. The CEO has confirmed that patients are not losing their hair from AVA6000, the pro-drug form of 'Red Devil'.
Bear in mind that 97% (thanks to Rah for the extract) of patients experience hair loss when dosing at 70mg/m2. Avacta are now dosing at a significantly higher 108mg/m2.
Approx 8-10 patients have been dosed. As Myles pointed out - AS' answer was not theoretical.
It's no wonder the company have selected 3996 after C1 data, relocated to a more expensive London location, escalated the dose twice, attracted top oncology talent, presented at the prestigious AACR and repeatedly told us "it's going *very* well".
RE: Of course it is working (to date…)29 Jun 2022 06:13
‘ What isn’t clear to is does the fact that 5140 isn’t harmful to mice also mean that it isn’t harmful to humans?’
Not necessarily. But then the independent safety team wouldn’t have continued the study, let alone increase the dose & again shortly. Nor would the company just last week state that the study was ‘progressing very well’ if it was harmful to humans.
RE: SP not reflecting what can be inferred28 Jun 2022 09:11
'SP not reflecting what can be inferred'
Which is superb for those that believe Avacta could be on the cusp of disrupting a (sadly) growing $60B market. More time to load up ahead of the 'big, big inflection point'. End of September will come around very quickly. Especially with Avacta's expectation of DE2 for C3 and 2x US sites to come online & contribute to P1A. To keep on track, I would be expecting both of these RNS's in July.
‘ It is odd though that big pharma or their agents and funds aren’t buying in big at such apparently low SP.’
Maybe you missed it, but Blackrock have been buying. We’ve also had a number of big buys including 400k+, plus multiple daily 10k chunks since April. So Avacta is clearly starting to gain interest.
We’re highly unlikely to see multiple funds enter a biotech stock during an oncology Phase 1A study IMO. Too many will see that as very high risk & won’t dedicate their time/money to the research of Avacta, let alone start to buy. Some will of course happily enter when the risk has reduced post readout at 500p+, for example. They will then have the full package of data to go by . Significant returns would be expected from that level if/once the tech is proven end of September. It’s all about risk & right now if you said to someone that Avacta are trying to create a ‘cancer drug without the side effects’ they would probably run a mile. That’s where time & research comes in.
This is one of those rare times when retail have the advantage over the II’s. Some retail will wait for the platform to be unlocked, but to be in with the chance of making some potentially serious returns, the time to be buying is as close to the year low of 40p as possible.
RE: Of course it is working (to date…)27 Jun 2022 21:25
It would show in the urine & bloods if it was remaining inert. The independent safety committee wouldn’t continue for 10 months, let alone agree to increase the dose if the Dox wasn’t being cut away from the enzyme.
Plus, just last week Avacta said ‘ALS-6000-001 progressing very well with key clinical readout later in the year’.
RE: Q1 2023 •AVA6000 FAPi PET Imaging Data25 Jun 2022 18:48
This was something that AS highlighted as new during his presentation. He didn’t talk too much about it, but it has clearly been added to their plan of action based on positive data from the study so far. You wouldn’t start this, let alone inform the market, if the platform was a dud.
I remember FMcL stating that they know how Dox performs once in the body. This well-understood drug, Doxorubicin, was never in question. As you’ve pointed out, one of the big unknowns was whether Dox was cut away too soon meaning healthy tissues were damaged & subsequently the study would’ve been stopped. It hasn’t. Instead they increased the dose back in February and are expected to again for cohort 3 too.
Due to ethical reasons they can’t say ‘we have biopsies’. They’ve done everything they can.
AS answered Myles’ question yesterday; ‘Have you received any biopsies yet?’
“I am very confident that we will have biopsy data when we put together the whole package, yes.”
This is the second (or third?) time that he’s stated that they’re *very* confident of obtaining biopsies. If people want to want for the RNS the that’s fair enough. But I have enough to be confident that they have 1-2. Especially given they had the assays prepped 2-3 months ago.